Evidence map›Paper›PMID 33442771›Full record

ArticlePsychopharmacology2021

Antipsychotic potential of the type 1 cannabinoid receptor positive allosteric modulator GAT211: preclinical in vitro and in vivo studies.

Dan L McElroy, Andrew J Roebuck, Gavin A Scott, Quentin Greba, Sumanta Garai, Eileen M Denovan-Wright, Ganesh A Thakur, Robert B Laprairie, John G Howland

Abstract read
PubMed Publisher
In one paragraph

Article in Psychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Cannabinoid receptor 1 positive allosteric modulator (GAT229) attenuates cisplatin-induced neuropathic pain in mice.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Dan L McElroyDepartment of Anatomy, Physiology, and Pharmacology, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK, S7N 5E5, Canada.
Andrew J RoebuckYukon University, Whitehorse, YT, Y1A 5K4, Canada.
Gavin A ScottHotchkiss Brain Institute, University of Calgary, Calgary, AB, T2N 4N1, Canada.
Quentin GrebaDepartment of Anatomy, Physiology, and Pharmacology, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK, S7N 5E5, Canada.
Sumanta GaraiDepartment of Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA.
Eileen M Denovan-WrightDepartment of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, NS, B3H 4R2, Canada.
Ganesh A ThakurDepartment of Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA.
Robert B LaprairieDepartment of Pharmacology, Faculty of Medicine, Dalhousie University, Halifax, NS, B3H 4R2, Canada.
John G HowlandDepartment of Anatomy, Physiology, and Pharmacology, University of Saskatchewan, 107 Wiggins Road, Saskatoon, SK, S7N 5E5, Canada. john.howland@usask.ca.ORCID http://orcid.org/0000-0003-3326-7118
University of Saskatchewan · CADalhousie University · CANortheastern University · USUniversity of Calgary · CAYukon University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleAntipsychotics help alleviate the positive symptoms associated with schizophrenia; however, their debilitating side effects have spurred the search for better treatment options. Novel compounds can be screened for antipsychotic potential in neuronal cell cultures and following acute N-methyl-D-aspartate (NMDA) receptor blockade with non-competitive antagonists such as MK-801 in rodent behavioral models. Given the known interactions between NMDA receptors and type 1 cannabinoid receptors (CB1R), compounds that modulate CB1Rs may have therapeutic potential for schizophrenia.

objectivesThis study assessed whether the CB1R positive allosteric modulator GAT211, when compared to ∆

methodsThe effects of GAT211 and THC on cellular signaling were compared in Neuro2a cells, and behavioral effects of GAT211 and THC on altered locomotor activity and prepulse inhibition of the acoustic startle response caused by acute MK-801 treatment were assessed in male, Long Evans rats.

resultsGAT211 limited dopamine D2 receptor-mediated extracellular regulated kinase (ERK) phosphorylation in Neuro2a cells, whereas THC did not. As expected, acute MK-801 (0.15 mg/kg) produced a significant increase in locomotor activity and impaired PPI. GAT211 treatment alone (0.3-3.0 mg/kg) dose-dependently reduced locomotor activity and the acoustic startle response. GAT211 (3.0 mg/kg) also prevented hyperlocomotion caused by MK-801 but did not significantly affect PPI impairments.

conclusionTaken together, these findings support continued preclinical research regarding the usefulness of CB1R positive allosteric modulators as antipsychotics.

Indexed as

AnimalsAntipsychotic AgentsBehavior, AnimalCell LineDizocilpine MaleateDose-Response Relationship, DrugDronabinolExcitatory Amino Acid AntagonistsExtracellular Signal-Regulated MAP KinasesIndolesMaleMotor ActivityPhosphorylationPrepulse InhibitionPsychoses, Substance-InducedRats3-(2-nitro-1-phenylethyl)-2-phenyl-1H-indoleAntipsychotic AgentsDizocilpine MaleateDronabinolExcitatory Amino Acid AntagonistsExtracellular Signal-Regulated MAP KinasesIndolesReceptor, Cannabinoid, CB1Acoustic startleCannabisMK-801NMDA receptorOpen fieldPrepulse inhibitionSchizophreniaTHC

Identifiers

PMID33442771
OpenAlexW3119582660

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.